Specifically, MHC-I glycosylation at the conserved Asn86 position influences interactions with molecular chaperones and other quality control molecules of the APP pathway, which mediate peptide repertoire optimization (Tapasin, TAPBPR, UGGT1), and could therefore influence  cancer antigen selection and presentation81–84. Here, TAPBPL is linked to cancer.